Our client executed a strategic acquisition, purchasing two distinct legacy product portfolios from two top-tier pharmaceutical companies.
A rapidly expanding biosimilars multinational operating in Asia faced critical supply chain distress, manifesting as escalating backorders despite perceived adequate capacity.
A major manufacturing company suffered from inconsistent production outputs and excess waste.